Headlands Technologies LLC Invests $4.46 Million in United Therapeutics Corporation $UTHR

Key Points

• Headlands Technologies initiated a $4.46 million position in United Therapeutics by purchasing 8,228 shares during the second quarter. Institutional investors collectively own 94.08% of the company.
• United Therapeutics exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus estimate, though revenue fell 1.9% year over year to $783.3 million.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $646, compared with the stock’s reported price of $515.46; meanwhile, company insiders sold $216.7 million in shares during the last quarter.

Headlands Technologies LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,228 shares of the biotechnology company's stock, valued at approximately $4,458,000.

Several other institutional investors have also bought and sold shares of the company. Callan Family Office LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $1,217,000. Leuthold Group LLC boosted its stake in United Therapeutics by 41.4% during the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock valued at $5,200,000 after buying an additional 3,126 shares during the period. Nicholas Investment Partners LP grew its holdings in shares of United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock worth $2,218,000 after purchasing an additional 3,766 shares in the last quarter. M&T Bank Corp grew its stake in United Therapeutics by 171.6% in the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company's stock worth $1,531,000 after buying an additional 1,985 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in United Therapeutics in the fourth quarter worth $633,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $515.46 on Monday. United Therapeutics Corporation has a 1-year low of $303.08 and a 1-year high of $609.35. The firm's 50-day moving average price is $530.46 and its 200-day moving average price is $539.16. The firm has a market capitalization of $22.11 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the firm earned $6.41 earnings per share. United Therapeutics's revenue was down 1.9% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Weiss Ratings lowered United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $646.00.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,185,323.93. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 404,575 shares of company stock worth $216,652,640 in the last quarter. Company insiders own 8.60% of the company's stock.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source